Read More 5 minute read Pharma Industry News Celcuity moves gedatolisib toward U.S. approval with NDA filing for HR+/HER2- advanced breast cancer patients Discover how Celcuity’s FDA review for gedatolisib could expand treatment choices for HR+/HER2- PIK3CA wild-type advanced breast cancer patients. bySoujanya RaviNovember 17, 2025